index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
32401,Pralatrexate for Peripheral T-Cell Lymphoma (PTCL),"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41549,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Pralatrexate for Peripheral T-Cell Lymphoma (PTCL), NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue",Pharmaceutical,pralatrexate vs. best supportive care,Not Stated,Not Stated,18 Years,"Male, Female",Full,10 Years,1.50,1.50,189133,Canada,2018,157519.56
32402,Pralatrexate for Peripheral T-Cell Lymphoma (PTCL),"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41549,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Pralatrexate for Peripheral T-Cell Lymphoma (PTCL), NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue",Pharmaceutical,pralatrexate vs. best supportive care,Not Stated,Not Stated,18 Years,"Male, Female",Full,10 Years,1.50,1.50,479307,Canada,2018,399191.18
32403,Cerliponase alfa for Neuronal Ceroid Lipofuscinosis Type 2,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41550,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Cerliponase alfa for Neuronal Ceroid Lipofuscinosis Type 2, NotApplicable, ; NotApplicable():",QALY,Canada,Metabolic disorders,Pharmaceutical,cerliponase alfa vs. best supportive care,Not Stated,Not Stated,0 Years,"Male, Female",Full,Lifetime,1.50,1.50,1811059,Canada,2017,1541967.4
32404,Cerliponase alfa for Neuronal Ceroid Lipofuscinosis Type 2,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41550,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Cerliponase alfa for Neuronal Ceroid Lipofuscinosis Type 2, NotApplicable, ; NotApplicable():",QALY,Canada,Metabolic disorders,Pharmaceutical,cerliponase alfa vs. best supportive care,Not Stated,Not Stated,0 Years,"Male, Female",Full,Lifetime,1.50,1.50,1718976,Canada,2017,1463566.32
32405,Dabrafenib & Trametinib in combo for Melanoma Adjuvant Therapy,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41552,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Dabrafenib & Trametinib in combo for Melanoma Adjuvant Therapy, NotApplicable, ; NotApplicable():",QALY,Canada,Melanoma and other malignant neoplasms of skin,Pharmaceutical,dabrafenib vs. watchful observation (i.e. placebo),r high-risk BRAF V600 mutation-positive melanoma patients after surgical resection,Not Stated,18 Years,"Male, Female",Full,35 Years,Not Stated,Not Stated,32399,Canada,2017,27585.08
32406,Dabrafenib & Trametinib in combo for Melanoma Adjuvant Therapy,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41552,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Dabrafenib & Trametinib in combo for Melanoma Adjuvant Therapy, NotApplicable, ; NotApplicable():",QALY,Canada,Melanoma and other malignant neoplasms of skin,Pharmaceutical,dabrafenib vs. watchful observation (i.e. placebo),r high-risk BRAF V600 mutation-positive melanoma patients after surgical resection,Not Stated,18 Years,"Male, Female",Full,35 Years,Not Stated,Not Stated,39339,Canada,2017,33493.91
32407,Dabrafenib & Trametinib in combo for Melanoma Adjuvant Therapy,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41552,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Dabrafenib & Trametinib in combo for Melanoma Adjuvant Therapy, NotApplicable, ; NotApplicable():",QALY,Canada,Melanoma and other malignant neoplasms of skin,Pharmaceutical,dabrafenib vs. watchful observation (i.e. placebo),r high-risk BRAF V600 mutation-positive melanoma patients after surgical resection,Not Stated,18 Years,"Male, Female",Full,35 Years,Not Stated,Not Stated,84271,Canada,2017,71749.81
32408,Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41574,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Extrapyramidal and movement disorders,Pharmaceutical,valbenazine vs. placebo,Underlying conditions of schizophrenia/schizoaffective disorders or affective disorders and on medications that cause tardive dyskinesia,64 Years,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,752080,United States,2016,849104.89
32409,Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41574,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Extrapyramidal and movement disorders,Pharmaceutical,deutetrabenazine vs. placebo,Underlying conditions of schizophrenia/schizoaffective disorders or affective disorders and on medications that cause tardive dyskinesia,64 Years,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1100773,United States,2016,1242782.33
32410,Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41557,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Pharmaceutical,inotersen vs. best supportive care,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1730000,United States,2018,1866846.01
32411,Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41557,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Pharmaceutical,inotersen vs. best supportive care,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1730000,United States,2018,1866846.01
32412,Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41557,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Pharmaceutical,patisiran vs. best supportive care,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,835000,United States,2018,901049.95
32413,Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41557,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Pharmaceutical,patisiran vs. best supportive care,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,853000,United States,2018,920473.78
32418,Abemaciclib for Metastatic Breast Cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41556,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Abemaciclib for Metastatic Breast Cancer, NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, breast and female genital organs",Pharmaceutical,abemaciclib vs. non-steroidal aromatase inhibitor,endocrine-naive/sensitive,Not Stated,18 Years,"Male, Female",Full,"37 Months, 28 Months",Not Stated,Not Stated,189609,Canada,2017,161436.43
32419,Abemaciclib for Metastatic Breast Cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41556,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Abemaciclib for Metastatic Breast Cancer, NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, breast and female genital organs",Pharmaceutical,abemaciclib vs. non-steroidal aromatase inhibitor,endocrine-naive/sensitive,Not Stated,18 Years,"Male, Female",Full,"37 Months, 28 Months",Not Stated,Not Stated,2125957,Canada,2017,1810077.09
32420,Abemaciclib for Metastatic Breast Cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41556,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Abemaciclib for Metastatic Breast Cancer, NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, breast and female genital organs",Pharmaceutical,abemaciclib vs. non-steroidal aromatase inhibitor,endocrine-naive/sensitive,Not Stated,18 Years,"Male, Female",Full,"37 Months, 28 Months",Not Stated,Not Stated,382342,Canada,2017,325532.69
32421,Abemaciclib for Metastatic Breast Cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41556,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Abemaciclib for Metastatic Breast Cancer, NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, breast and female genital organs",Pharmaceutical,abemaciclib vs. fulvestrant,endocrine-resistant,Not Stated,18 Years,"Male, Female",Full,"37 Months, 28 Months",Not Stated,Not Stated,430659,Canada,2017,366670.63
32422,Abemaciclib for Metastatic Breast Cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41556,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Abemaciclib for Metastatic Breast Cancer, NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, breast and female genital organs",Pharmaceutical,abemaciclib vs. fulvestrant,endocrine-resistant,Not Stated,18 Years,"Male, Female",Full,"37 Months, 28 Months",Not Stated,Not Stated,2115150,Canada,2017,1800875.82
32423,Abemaciclib for Metastatic Breast Cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41556,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Abemaciclib for Metastatic Breast Cancer, NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, breast and female genital organs",Pharmaceutical,abemaciclib vs. fulvestrant,endocrine-resistant,Not Stated,18 Years,"Male, Female",Full,"37 Months, 28 Months",Not Stated,Not Stated,448508,Canada,2017,381867.58
32424,"Sucroferric oxyhydroxide for Hyperphosphatemia, end-stage renal disease","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41546,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Sucroferric oxyhydroxide for Hyperphosphatemia, end-stage renal disease, NotApplicable, ; NotApplicable():",QALY,Canada,Renal failure,Pharmaceutical,sucroferric oxyhydroxide vs. sevelamer hydrochloride,"on dialysis, experiencing hyperphosphatemia",Not Stated,18 Years,"Male, Female",Full,10 Years,1.50,1.50,2870896,Canada,2018,2391027.8
32425,"Sucroferric oxyhydroxide for Hyperphosphatemia, end-stage renal disease","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41546,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Sucroferric oxyhydroxide for Hyperphosphatemia, end-stage renal disease, NotApplicable, ; NotApplicable():",QALY,Canada,Renal failure,Pharmaceutical,sucroferric oxyhydroxide vs. sevelamer carbonate,"on dialysis, experiencing hyperphosphatemia",Not Stated,18 Years,"Male, Female",Full,10 Years,1.50,1.50,22636505,Canada,2018,18852829.51
32426,"Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41566,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks, NotApplicable, ; NotApplicable():",QALY,United States of America,Chronic lower respiratory diseases,Pharmaceutical,omalizumab vs. inhaled corticosteroids,type 2 inflammation,Not Stated,6 Years,"Male, Female",Full,Lifetime,3.00,3.00,325000,United States,2018,350708.06
32427,"Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41566,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks, NotApplicable, ; NotApplicable():",QALY,United States of America,Chronic lower respiratory diseases,Pharmaceutical,mepolizumab vs. inhaled corticosteroids,type 2 inflammation,Not Stated,6 Years,"Male, Female",Full,Lifetime,3.00,3.00,344000,United States,2018,371211
32428,"Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41566,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks, NotApplicable, ; NotApplicable():",QALY,United States of America,Chronic lower respiratory diseases,Pharmaceutical,reslizumab vs. inhaled corticosteroids,type 2 inflammation,Not Stated,6 Years,"Male, Female",Full,Lifetime,3.00,3.00,391000,United States,2018,421928.78
32429,"Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41566,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks, NotApplicable, ; NotApplicable():",QALY,United States of America,Chronic lower respiratory diseases,Pharmaceutical,benralizumab vs. inhaled corticosteroids,type 2 inflammation,Not Stated,6 Years,"Male, Female",Full,Lifetime,3.00,3.00,371000,United States,2018,400346.74
32430,"Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41566,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks, NotApplicable, ; NotApplicable():",QALY,United States of America,Chronic lower respiratory diseases,Pharmaceutical,dupilumab vs. inhaled corticosteroids,type 2 inflammation,Not Stated,6 Years,"Male, Female",Full,Lifetime,3.00,3.00,351000,United States,2018,378764.71
32431,Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41569,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Disorders of choroid and retina,Pharmaceutical,voretigene neparvovec vs. supportive care,,15 Years,15 Years,"Male, Female",Full,Lifetime,3.00,3.00,643813,United States,2017,711708.59
32432,Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41569,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Disorders of choroid and retina,Pharmaceutical,voretigene neparvovec vs. supportive care,Not Stated,15 Years,15 Years,"Male, Female",Full,Lifetime,3.00,3.00,480130,United States,2017,530763.81
32433,Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41569,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Disorders of choroid and retina,Pharmaceutical,voretigene neparvovec vs. supportive care,Not Stated,3 Years,3 Years,"Male, Female",Full,Lifetime,3.00,3.00,287915,United States,2017,318278.1
32434,Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41569,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Disorders of choroid and retina,Pharmaceutical,voretigene neparvovec vs. supportive care,Not Stated,3 Years,3 Years,"Male, Female",Full,Lifetime,3.00,3.00,135331,United States,2017,149602.81
32435,Elagolix for Treating Endometriosis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41573,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Elagolix for Treating Endometriosis, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninflammatory disorders of female genital tract,Pharmaceutical,elagolix vs. no active treatment,"premenopausal, moderate-to-severe pain",50 Years,32 Years,Female,Full,"18 Years, 6 Months",3.00,3.00,126800,United States,2018,136830.1
32436,Elagolix for Treating Endometriosis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41573,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Elagolix for Treating Endometriosis, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninflammatory disorders of female genital tract,Pharmaceutical,elagolix vs. no active treatment,"premenopausal, moderate-to-severe pain",50 Years,32 Years,Female,Full,"18 Years, 6 Months",3.00,3.00,81000,United States,2018,87407.24
32437,Vedolizumab for Ulcerative Colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41533,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for Ulcerative Colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"tofacitinib vs. conventional therapy (mesalazine, azathioprine, and prednisolone)","anti-tumor necrosis factor alpha naïve, moderately to severely active ulcerative colitis",Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,91883,Canada,2018,76524.82
32438,Vedolizumab for Ulcerative Colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41533,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for Ulcerative Colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"vedolizumab subcutaneous vs. conventional therapy (mesalazine, azathioprine, and prednisolone)","anti-tumor necrosis factor alpha naive, moderately to severely active ulcerative colitis",Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,146005,Canada,2018,121600.37
32439,Vedolizumab for Ulcerative Colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41533,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for Ulcerative Colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,vedolizumab subcutaneous vs. tofacitinib,"anti-tumor necrosis factor alpha naïve, moderately to severely active ulcerative colitis",Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-172235.77,Canada,2018,-143446.69
32440,Vedolizumab for Ulcerative Colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41533,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for Ulcerative Colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"tofacitinib vs. conventional therapy (mesalazine, azathioprine, and prednisolone)","anti-tumor necrosis factor alpha exposed, moderately to severely active ulcerative colitis",Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,117761,Canada,2018,98077.33
32441,Vedolizumab for Ulcerative Colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41533,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for Ulcerative Colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"vedolizumab subcutaneous vs. conventional therapy (mesalazine, azathioprine, and prednisolone)","anti-tumor necrosis factor alpha exposed, moderately to severely active ulcerative colitis",Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,155159,Canada,2018,129224.29
32442,Vedolizumab for Ulcerative Colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41533,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for Ulcerative Colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,vedolizumab subcutaneous vs. tofacitinib,"anti-tumor necrosis factor alpha exposed, moderately to severely active ulcerative colitis",Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,1152959,Canada,2018,960242.73
32443,Iron (III) Isomaltoside 1000 for iron deficiency anemia,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41537,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Iron (III) Isomaltoside 1000 for iron deficiency anemia, NotApplicable, ; NotApplicable():",QALY,Canada,Nutritional anaemias,Pharmaceutical,"IV iron isomaltoside 1000 vs. Venofer, intravenous iron sucrose",adult patients who have an intolerance or unresponsiveness to oral iron therapy,Not Stated,18 Years,"Male, Female",Full,6 Months,Not Stated,Not Stated,-57084.62,Canada,2018,-47542.96
32444,"Brentuximab Vedotin for Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41539,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Brentuximab Vedotin for Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD), NotApplicable, ; NotApplicable():",QALY,Canada,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue",Pharmaceutical,brentuximab vedotin vs. doxorubicin,previously untreated stage iv hodgkin lymphoma,Not Stated,18 Years,"Male, Female",Full,Lifetime,Not Stated,Not Stated,134059,Canada,2018,111651.13
32445,Tafamidis for transthyretin-mediated amyloidosis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41540,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Tafamidis for transthyretin-mediated amyloidosis, NotApplicable, ; NotApplicable():",QALY,Canada,"Metabolic disorders, Other forms of heart disease",Pharmaceutical,tafamidis meglumine vs. best supportive care,cardiomyopathy due to wild-type or hereditary transthyretin mediated amyloid,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,443694,Canada,2018,369530.87
32446,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,infliximab vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,185071,Canada,2019,147822.87
32447,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,secukinumab vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-32824.95,Canada,2019,-26218.47
32448,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,upadacitinib vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-51563,Canada,2019,-41185.23
32449,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,certolizumab pegol vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-45303.49,Canada,2019,-36185.53
32450,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ixekizumab vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-36683.75,Canada,2019,-29300.63
32451,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ixekizumab vs. infliximab,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-5304.4,Canada,2019,-4236.82
32452,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ustekinumab vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-38591.11,Canada,2019,-30824.11
32453,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ustekinumab vs. infliximab,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-6621.35,Canada,2019,-5288.71
32454,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,adalimumab vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-47470.19,Canada,2019,-37916.15
32455,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,adalimumab vs. infliximab,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-10052.93,Canada,2019,-8029.64
32456,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,golimumab vs. etanercept,biologic-naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-132931.62,Canada,2019,-106177.27
32457,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,golimumab vs. infliximab,biologic-naive,Not Stated,18 Years,Female,Full,Lifetime,1.50,1.50,-29676.3,Canada,2019,-23703.53
32458,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ustekinumab vs. secukinumab,biologic-experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-8616.75,Canada,2019,-6882.51
32459,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,upadacitinib vs. secukinumab,biologic-experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-22766.67,Canada,2019,-18184.56
32460,Upadacitinib for Adult Psoriatic Arthritis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41532,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Upadacitinib for Adult Psoriatic Arthritis, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ixekizumab vs. secukinumab,biologic-experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,1.50,1.50,-72941.18,Canada,2019,-58260.74
32461,Sonidegib for Basal Cell Carcinoma,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41535,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Sonidegib for Basal Cell Carcinoma, NotApplicable, ; NotApplicable():",QALY,Canada,Melanoma and other malignant neoplasms of skin,Pharmaceutical,sonidegib vs. vismodegib,adult patients with histologically confirmed locally advanced basal cell carcinoma that is not amenable to radiation therapy or curative surgery,Not Stated,18 Years,"Male, Female",Full,10 Years,Not Stated,Not Stated,-252752.81,Canada,2019,-201882.77
32462,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,rituximab vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,198056,United States,2015,226427.79
32463,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,abatacept intravenous vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,191317,United States,2015,218723.41
32464,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,abatacept subcutaneous vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,225853,United States,2015,258206.74
32465,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tocilizumab intravenous vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,183949,United States,2015,210299.94
32466,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tocilizumab subcutaneous vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,168660,United States,2015,192820.77
32467,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tofacitinib vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,271749,United States,2015,310677.41
32468,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,adalimumab vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,232644,United States,2015,265970.56
32469,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,certolizumab pegol vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,209736,United States,2015,239780.96
32470,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,etanercept vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,212021,United States,2015,242393.29
32471,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,golimumab subcutaneous vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,222380,United States,2015,254236.23
32472,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,golimumab intravenous vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,204212,United States,2015,233465.64
32473,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,infliximab vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,202824,United States,2015,231878.81
32474,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,rituximab vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-3292800,United States,2015,-3764497.97
32475,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,abatacept intravenous vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-639870,United States,2015,-731532.23
32476,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,abatacept subcutaneous vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,163376,United States,2015,186779.83
32477,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tocilizumab intravenous vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-300325,United States,2015,-343346.96
32478,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tocilizumab subcutaneous vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-812276.92,United States,2015,-928636.67
32479,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tofacitinib vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-440181.82,United States,2015,-503238.45
32480,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,certolizumab pegol vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-45816.67,United States,2015,-52379.97
32481,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,etanercept vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,119233,United States,2015,136313.29
32482,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,golimumab subcutaneous vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-1784500,United States,2015,-2040131.99
32483,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,golimumab intravenous vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-598428.57,United States,2015,-684154.26
32484,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,infliximab vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-996440,United States,2015,-1139181.35
32485,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tocilizumab intravenous monotherapy vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,162038,United States,2015,185250.16
32486,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,tocilizumab intravenous monotherapy vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-183017.5,United States,2015,-209235
32487,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,adalimumab monotherapy vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,225423,United States,2015,257715.14
32488,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,etanercept monotherapy vs. conventional disease-modifying anti-rheumatic drugs,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,214427,United States,2015,245143.95
32489,Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2017-01-41579,,NotApplicable,NotApplicable,2017,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Rheumatoid arthritis,Pharmaceutical,etanercept monotherapy vs. adalimumab,"moderately to severely active rheumatoid arthritis, inadequate response/intolerance of conventional disease-modifying anti-rheumatic drugs",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,102697,United States,2015,117408.48
32490,Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2011-01-41585,,NotApplicable,NotApplicable,2011,NotApplicable /,,No,Not Stated,"NotApplicable; Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer, NotApplicable, ; NotApplicable():",QALY,United Kingdom,Malignant neoplasms of respiratory and intrathoracic organs,Pharmaceutical,erlotinib vs. best supportive care: palliative radiotherapy,"stable squamous disease, stage IIIB or stage IV, treated with standard platinum-based first-line chemotherapy",Not Stated,18 Years,"Male, Female",Full,15 Years,Not Stated,Not Stated,44812,United Kingdom,2009,81952.12
32491,Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2011-01-41585,,NotApplicable,NotApplicable,2011,NotApplicable /,,No,Not Stated,"NotApplicable; Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer, NotApplicable, ; NotApplicable():",QALY,United Kingdom,Malignant neoplasms of respiratory and intrathoracic organs,Pharmaceutical,erlotinib vs. best supportive care: palliative radiotherapy,"stable non-squamous disease, treated with standard platinum-based first-line chemotherapy, stage IIIB or stage IV",Not Stated,18 Years,"Male, Female",Full,15 Years,Not Stated,Not Stated,68120,United Kingdom,2009,124577.75
32492,Dronedarone for the treatment of non-permanent atrial fibrillation,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2012-01-41604,,NotApplicable,NotApplicable,2012,NotApplicable /,,No,Not Stated,"NotApplicable; Dronedarone for the treatment of non-permanent atrial fibrillation, NotApplicable, ; NotApplicable():",QALY,United Kingdom,Other forms of heart disease,Pharmaceutical,dronedarone vs. standard baseline therapy: sotalol,CHADS2 score of 4 or more,Not Stated,18 Years,"Male, Female",Full,Lifetime,Not Stated,Not Stated,1895,United Kingdom,2010,3635.38
32493,Dronedarone for the treatment of non-permanent atrial fibrillation,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2012-01-41604,,NotApplicable,NotApplicable,2012,NotApplicable /,,No,Not Stated,"NotApplicable; Dronedarone for the treatment of non-permanent atrial fibrillation, NotApplicable, ; NotApplicable():",QALY,United Kingdom,Other forms of heart disease,Pharmaceutical,dronedarone vs. standard baseline therapy: sotalol,CHADS2 score of 4 or more,Not Stated,18 Years,"Male, Female",Full,Lifetime,Not Stated,Not Stated,4014,United Kingdom,2010,7700.48
32494,Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2014-01-41598,,NotApplicable,NotApplicable,2014,NotApplicable /,,No,Not Stated,"NotApplicable; Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma, NotApplicable, ; NotApplicable():",QALY,United Kingdom,Melanoma and other malignant neoplasms of skin,Pharmaceutical,150 mg of dabrafenib twice daily orally vs. dacarbazine by intravenous infusion every 3 weeks,BRAF V600 mutation positive,Not Stated,18 Years,"Male, Female",Full,30 Years,3.50,3.50,49019,United Kingdom,2012,91715.61
32495,Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2014-01-41598,,NotApplicable,NotApplicable,2014,NotApplicable /,,No,Not Stated,"NotApplicable; Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma, NotApplicable, ; NotApplicable():",QALY,United Kingdom,Melanoma and other malignant neoplasms of skin,Pharmaceutical,150 mg of dabrafenib twice daily orally vs. vemurafenib 960 mg twice daily orally,BRAF V600 mutation positive,Not Stated,18 Years,"Male, Female",Full,30 Years,3.50,3.50,11028,United Kingdom,2012,20633.63
32498,Mepolizumab for severe eosinophilic asthma,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41534,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Mepolizumab for severe eosinophilic asthma, NotApplicable, ; NotApplicable():",QALY,Canada,Chronic lower respiratory diseases,Pharmaceutical,Mepolizumab vs. standard of care (inhaled corticosteroids + additional controller medication),severe eosinophilic asthma (≥ 150 cells/mcL at treatment initiation or ≥ 300 cells/mcL in past 12 months); allergic asthma,65 Years,30 Years,"Male, Female",Full,"Lifetime, 10 Years",5.00,5.00,143778,Canada,2015,128708.78
32499,Mepolizumab for severe eosinophilic asthma,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41534,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Mepolizumab for severe eosinophilic asthma, NotApplicable, ; NotApplicable():",QALY,Canada,Chronic lower respiratory diseases,Pharmaceutical,Mepolizumab vs. standard of care,severe eosinophilic asthma (≥ 150 cells/mcL at treatment initiation or ≥ 300 cells/mcL in past 12 months); allergic asthma,65 Years,30 Years,"Male, Female",Full,"Lifetime, 10 Years",5.00,5.00,521838,Canada,2015,467144.71
32500,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,dapagliflozin vs. empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-2387.1,United Kingdom,2012,-4466.31
